MacroGenics Gets Nod For Margenza In HER2-Positive Breast Cancer
Company Reaches Milestone With First FDA Approval
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.